Movement Alert｜Hansoh Pharmaceutical Rises 3.5% in Regular Trading, Subsidiary Avere to Merge into Nasdaq-Listed NextCure

Market Focus07-15

On July 15, Hansoh Pharmaceutical rose 3.5% in regular trading, trading at HKD 33.7/share, with turnover of HKD 166 million.

On the news front, Hansoh announced on July 14 that its subsidiary Avere Therapeutics will merge into Nasdaq-listed biotechnology company NextCure Inc. pursuant to a merger agreement signed on the same date. The transaction aims to integrate both parties' resources and expertise in innovative therapeutics, advancing Hansoh's internationalization strategy.

The merger news comes on the heels of another significant catalyst. On July 10, Hansoh disclosed that its self-developed B7-H3 targeted antibody-drug conjugate HS-20093 achieved the primary endpoint of overall survival in a pivotal Phase III trial for small cell lung cancer patients who progressed after platinum-containing therapy. This represents the first global Phase III study demonstrating significant OS benefit from a B7-H3 ADC in SCLC. The company plans to advance its new drug application filing with regulators.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1179267531?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-15 09:55","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1179267531","market":"us","top_or_hot":-1,"title":"Movement Alert｜Hansoh Pharmaceutical Rises 3.5% in Regular Trading, Subsidiary Avere to Merge into Nasdaq-Listed NextCure","media":"Market Focus","content":"<p><p>On July 15, Hansoh Pharmaceutical rose 3.5% in regular trading, trading at HKD 33.7/share, with turnover of HKD 166 million.</p><p>On the news front, Hansoh announced on July 14 that its subsidiary Avere Therapeutics will merge into Nasdaq-listed biotechnology company NextCure Inc. pursuant to a merger agreement signed on the same date. The transaction aims to integrate both parties' resources and expertise in innovative therapeutics, advancing Hansoh's internationalization strategy.</p><p>The merger news comes on the heels of another significant catalyst. On July 10, Hansoh disclosed that its self-developed B7-H3 targeted antibody-drug conjugate HS-20093 achieved the primary endpoint of overall survival in a pivotal Phase III trial for small cell lung cancer patients who progressed after platinum-containing therapy. This represents the first global Phase III study demonstrating significant OS benefit from a B7-H3 ADC in SCLC. The company plans to advance its new drug application filing with regulators.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Hansoh Pharmaceutical Rises 3.5% in Regular Trading, Subsidiary Avere to Merge into Nasdaq-Listed NextCure</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Hansoh Pharmaceutical Rises 3.5% in Regular Trading, Subsidiary Avere to Merge into Nasdaq-Listed NextCure\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-15 09:55</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 15, Hansoh Pharmaceutical rose 3.5% in regular trading, trading at HKD 33.7/share, with turnover of HKD 166 million.</p><p>On the news front, Hansoh announced on July 14 that its subsidiary Avere Therapeutics will merge into Nasdaq-listed biotechnology company NextCure Inc. pursuant to a merger agreement signed on the same date. The transaction aims to integrate both parties' resources and expertise in innovative therapeutics, advancing Hansoh's internationalization strategy.</p><p>The merger news comes on the heels of another significant catalyst. On July 10, Hansoh disclosed that its self-developed B7-H3 targeted antibody-drug conjugate HS-20093 achieved the primary endpoint of overall survival in a pivotal Phase III trial for small cell lung cancer patients who progressed after platinum-containing therapy. This represents the first global Phase III study demonstrating significant OS benefit from a B7-H3 ADC in SCLC. The company plans to advance its new drug application filing with regulators.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03692","symbol_name":"翰森制药","start_time":0,"source_url":"","article_id":"1179267531","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1179267531","pubTimestamp":1784080548,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 15, Hansoh Pharmaceutical rose 3.5% in regular trading, trading at HKD 33.7/share, with turnover of HKD 166 million.On the news front, Hansoh announced on July 14 that its subsidiary Avere...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03692":"翰森制药"},"translate_title":"走势提醒|豪森制药常规交易上涨3.5%，子公司Avere将并入纳斯达克上市公司NextCure","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03692":1},"content_text":"On July 15, Hansoh Pharmaceutical rose 3.5% in regular trading, trading at HKD 33.7/share, with turnover of HKD 166 million.On the news front, Hansoh announced on July 14 that its subsidiary Avere Therapeutics will merge into Nasdaq-listed biotechnology company NextCure Inc. pursuant to a merger agreement signed on the same date. The transaction aims to integrate both parties' resources and expertise in innovative therapeutics, advancing Hansoh's internationalization strategy.The merger news comes on the heels of another significant catalyst. On July 10, Hansoh disclosed that its self-developed B7-H3 targeted antibody-drug conjugate HS-20093 achieved the primary endpoint of overall survival in a pivotal Phase III trial for small cell lung cancer patients who progressed after platinum-containing therapy. This represents the first global Phase III study demonstrating significant OS benefit from a B7-H3 ADC in SCLC. The company plans to advance its new drug application filing with regulators.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.46.0","shortVersion":"4.46.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1179267531","isCrawlerRequest":true}